Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Yun Han Huang; Reed Magleby; Rema Rao; Thomas J. Walsh; Harjot K. Singh

doi:10.1016/j.mmcr.2021.03.004

Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Yun Han Huang, Reed Magleby, Rema Rao, Thomas J. Walsh, Harjot K. Singh

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with Histoplasma encapsulatum. To our knowledge, this is the first reported case of newly acquired histoplasmosis complicating treatment with ustekinumab.

Original language	English (US)
Pages (from-to)	43-46
Number of pages	4
Journal	Medical Mycology Case Reports
Volume	32
DOIs	https://doi.org/10.1016/j.mmcr.2021.03.004
State	Published - Jun 2021
Externally published	Yes

Keywords

Histoplasmosis
Immunosuppression
Ustekinumab

ASJC Scopus subject areas

Microbiology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mmcr.2021.03.004

Cite this

@article{cd9e05fc11d64786b56f41caac8c968b,

title = "Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy",

abstract = "Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with Histoplasma encapsulatum. To our knowledge, this is the first reported case of newly acquired histoplasmosis complicating treatment with ustekinumab.",

keywords = "Histoplasmosis, Immunosuppression, Ustekinumab",

author = "Huang, {Yun Han} and Reed Magleby and Rema Rao and Walsh, {Thomas J.} and Singh, {Harjot K.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jun,

doi = "10.1016/j.mmcr.2021.03.004",

language = "English (US)",

volume = "32",

pages = "43--46",

journal = "Medical Mycology Case Reports",

issn = "2211-7539",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Histoplasmosis in an off-trail Hiker receiving ustekinumab

T2 - Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

AU - Huang, Yun Han

AU - Magleby, Reed

AU - Rao, Rema

AU - Walsh, Thomas J.

AU - Singh, Harjot K.

PY - 2021/6

Y1 - 2021/6

N2 - Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with Histoplasma encapsulatum. To our knowledge, this is the first reported case of newly acquired histoplasmosis complicating treatment with ustekinumab.

AB - Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with Histoplasma encapsulatum. To our knowledge, this is the first reported case of newly acquired histoplasmosis complicating treatment with ustekinumab.

KW - Histoplasmosis

KW - Immunosuppression

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=85102635506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102635506&partnerID=8YFLogxK

U2 - 10.1016/j.mmcr.2021.03.004

DO - 10.1016/j.mmcr.2021.03.004

M3 - Article

AN - SCOPUS:85102635506

SN - 2211-7539

VL - 32

SP - 43

EP - 46

JO - Medical Mycology Case Reports

JF - Medical Mycology Case Reports

ER -

Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this